•
Sep 30, 2021
Vera Q3 2021 Earnings Report
Vera Therapeutics reported third quarter 2021 financial results and provided a corporate update.
Key Takeaways
Vera Therapeutics reported a net loss of $7.6 million for the third quarter of 2021 and approximately $86.2 million in cash and cash equivalents as of September 30, 2021. The company is making progress in evaluating atacicept.
Ongoing progress in several areas evaluating atacicept.
Phase 2a JANUS clinical trial showed atacicept administered subcutaneously once weekly demonstrated a durable and substantial reduction in serum galactose-deficient IgA1 (Gd-IgA1) in a dose-dependent manner up to 72 weeks in patients with IgA nephropathy
Vera reported approximately $86.2 million in cash and cash equivalents as of September 30, 2021
Atacicept 75mg reduces Gd-IgA1 to the lowest risk quartile.